Rapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer; First-ever human use of eRapa in clinical trial at UT Health San Antonio MD Anderson Cancer Center will test safety, effective dose an

  • Michael A Liss

Press/Media: Press / Media

PeriodSep 18 2018 → Sep 19 2018

Media coverage

14

Media coverage

  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
    Media name/outletPlus Company Updates (PCU)
    CountryUnited States
    Date9/19/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer; First-ever human use of eRapa in clinical trial at UT Health San Antonio MD Anderson Cancer Center will test safety, effective dose an
    Media name/outletBusiness Wire
    CountryUnited States
    Date9/18/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer; First-ever human use of eRapa in clinical trial at UT Health San Antonio MD Anderson Cancer Center will test safety, effective dose an
    Media name/outletBusiness Wire
    CountryUnited States
    Date9/18/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
    Media name/outletBusiness Wire
    CountryUnited States
    Date9/18/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
    Media name/outletMorningstar.com
    CountryUnited States
    Date9/18/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
    Media name/outletNewStage.com.ng
    CountryNigeria
    Date9/18/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
    Media name/outletBioSpace
    CountryUnited States
    Date9/18/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
    Media name/outletCIT
    CountryUnited States
    Date9/18/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
    Media name/outletBristol Herald Courier
    CountryUnited States
    Date9/18/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
    Media name/outletTullahoma News
    CountryUnited States
    Date9/18/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
    Media name/outletGalveston County Daily News
    CountryUnited States
    Date9/18/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
    Media name/outletDaily American
    CountryUnited States
    Date9/18/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
    Media name/outletClarksburg Exponent Telegram
    CountryUnited States
    Date9/18/18
    PersonsMichael A Liss
  • TitleRapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
    Media name/outletPress of Atlantic City
    CountryUnited States
    Date9/18/18
    PersonsMichael A Liss